Experimental CAR-T therapies developed by Cabaletta Bio and Bristol Myers Squibb have demonstrated the ability to induce complete remissions in patients suffering from severe...
The treatment landscape for patients with relapsed multiple myeloma is evolving, with the introduction of therapies such as CAR T, bispecific antibodies, and antibody-drug...